XML 43 R30.htm IDEA: XBRL DOCUMENT v3.23.3
BUSINESS SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Summary of Segment Reporting Information by Segment The following table is a summary of segment information for the three and nine months ended September 30, 2023 and 2022. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2022 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net revenues:    
DIS business$2,228 $2,419 $6,755 $7,344 
All other operating segments67 67 209 206 
Total net revenues $2,295 $2,486 $6,964 $7,550 
Operating earnings (loss):    
DIS business$392 $441 $1,176 $1,445 
All other operating segments8 3 26 16 
General corporate activities(58)(52)(207)(168)
Total operating income342 392 995 1,293 
Non-operating expense, net(43)(41)(102)(167)
Income before income taxes and equity in earnings of equity method investees299 351 893 1,126 
Income tax expense(68)(81)(208)(268)
Equity in earnings of equity method investees, net of taxes6 6 18 41 
Net income237 276 703 899 
Less: Net income attributable to noncontrolling interests12 20 41 54 
Net income attributable to Quest Diagnostics$225 $256 $662 $845 
Schedule of Revenues by Major Service by major service for the three and nine months ended September 30, 2023 and 2022 were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Routine clinical testing and other services51 %45 %50 %43 %
COVID-19 testing services1 13 3 17 
Gene-based and esoteric (including advanced diagnostics) testing services39 33 38 31 
Anatomic pathology testing services6 6 6 6 
All other3 3 3 3 
Net revenues100 %100 %100 %100 %